Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Ferroportin mutation in autosomal dominant hemochromatosis: loss of function, gain in understanding
Robert E. Fleming, William S. Sly
Robert E. Fleming, William S. Sly
Published August 15, 2001
Citation Information: J Clin Invest. 2001;108(4):521-522. https://doi.org/10.1172/JCI13739.
View: Text | PDF
Commentary

Ferroportin mutation in autosomal dominant hemochromatosis: loss of function, gain in understanding

  • Text
  • PDF
Abstract

Authors

Robert E. Fleming, William S. Sly

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Ferroportin1 in absorption of dietary iron (a) and release of iron store...
Ferroportin1 in absorption of dietary iron (a) and release of iron stores (b). (a) Dietary nonheme iron at the luminal surface of the villus enterocyte is reduced by ferric reductase and taken up by DMT1. The iron may be retained, or transported across the basolateral surface by ferroportin1 (blue oval), oxidized by hephaestin, and bound to transferrin (Tf) for plasma transport. (b) Transferrin-bound iron (Tf-Fe) is taken up by the RE cell by a complex containing β2-microglobulin (β2M), the transferrin receptor (TfR), and the HFE protein (teal oval), which is defective in the classic, autosomal recessive form of hemochromatosis. Heme iron taken up by phagocytosis of senescent erythrocytes (RBC) is released by heme oxygenase (H.O.). The iron may be stored as ferritin, or exported via ferroportin1, after which it is oxidized by ceruloplasmin (Cp), and bound to transferrin for plasma transport. Hephaestin and ceruloplasmin, both indicated by green circles, are structurally similar and perform analogous functions, but their patterns of expression are distinct. Two recent papers, including one in this issue of the JCI, have implicated ferroportin in an atypical, autosomal dominant form of hemochromatosis (6, 7).

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts